Anna Wienner – General Manager, IBSA Hungary
Anna Wienner, general manager of IBSA Hungary, gives an update on the recent activities and achievement of the affiliate since her previous interview in 2016. Furthermore, Wienner goes on to…
Founded in 1908, LEO Pharma is an independent, research-based pharmaceutical company.
LEO Pharma develops, manufactures and markets pharmaceutical drugs to dermatologic and thrombotic patients in more than 100 countries globally. To realise our vision of becoming the preferred dermatology care partner improving people’s lives around the world, we are expanding into new regions and markets, reaching more patients and societies with drugs and therapies that address unmet medical needs.
LEO Pharma has its own sales forces in 61 countries and employs around 5,000 employees worldwide and generates approximately USD 1.2 billion in annual turnover. The company is headquartered in Denmark and is wholly owned by the LEO Foundation.
2015 was the year LEO Pharma embarked on our ‘Helping SARAH – LEO towards 2020’ journey – a new strategy which was launched in December 2014. With the ambitious aspiration to help more than 100 million people in 2020, LEO Pharma has committed itself to looking at new and innovative solutions and keeping engaging in partnerships to reach its goal. LEO Pharma wants to offer solutions in all aspects of life for people living with skin diseases, to assist them in taking control of their condition and improve their quality of life. We have set out on a mission to help people achieve healthy skin; in addition to our products, we offer patients a growing list of solutions and services. As part of our 2020 strategy, we have established LEO Innovation Lab, a separate business unit operating independently outside our traditional business. LEO Innovation Lab works to improve the well-being of people living with psoriasis by developing digital solutions and services. Generic competition is today a market condition when running a pharmaceutical business with strong products and solutions, and 2015 was no exception. This year we upheld our patents for Daivobet® Ointment in court rulings in the UK and Canada. The result for 2015 is considered satisfactory
Contact
LEO Pharma A/S Hungarian Commercial Representative Office
Regus Obuda Gate
Arpad fejedelem utja 26-28., 5th floor
1023 Budapest
Hungary
Tel. (+36) 1 888 0525
Anna Wienner, general manager of IBSA Hungary, gives an update on the recent activities and achievement of the affiliate since her previous interview in 2016. Furthermore, Wienner goes on to…
Norbert Langen, founder and CEO of Phytotec, a Hungarian distributor of evidence-based natural Rx and OTC drugs, introduces the company and its unique approach to marketing non-chemically formulated pharmaceuticals in…
Dr Ildikó Horvath, Hungary’s State Secretary for Health explains her role and shares insights on the key health trends in Hungary, the government’s top priority in improving healthcare, the importance…
Here we highlight five of the most important women working in healthcare and the life sciences in Central & Eastern Europe (CEE) today. From regulators to pharma affiliate heads with…
As the only one of Hungary’s four historical pharmaceutical manufactures to have resisted international acquisition, Gedeon Richter stands alone as the country’s national champion. However, the company does not exist…
Established in Hungary in 1913, Egis is a traditional Central Eastern European pharmaceutical company with an international footprint across the globe. As one of the four largest historical pharma companies…
Gábor Orbán, CEO of Gedeon Richter, highlights the recent turnaround of the company’s performance, its exciting new collaboration with Allergan in the US market, and the landmark launch of Gedeon’s…
Dr Péter Holchacker, director of the Hungarian Association of Innovative Pharmaceutical Manufacturers (AIPM), shares his insights on the key activities of the organisation, the collaborations it fosters with authorities and…
Attila Lukács, general manager Hungary, Romania, Bulgaria for CSL Behring outlines emergent trends in the Hungarian plasma medication market, how the affiliate has succeeded in becoming a partner to patient…
Laszlo Dinca, managing director of Vanessa Research – Hungary, shares his insights on the company’s rare and orphan disease portfolio; the intentions behind the acquisition of Hungaro-Gal Pharmaceutical Manufacturing [HG…
Irma Veberic, general manager of Roche Hungary, gives her insights on the key issues being faced by the Hungarian healthcare system and the company’s role as a partner in improving…
István Peták, co-founder and CEO of Oncompass introduces the innovative start-up and elaborates on how its solution for digital treatment planning and digital biomarkers can revolutionize not only personalized oncology…
See our Cookie Privacy Policy Here
